CAROLINA MARTINS DO PRADO
Projetos de Pesquisa
Unidades Organizacionais
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
conferenceObject ABCB1 and HTR2A Polymorphism may be Related to Treatment Response in a Sample of Mood Disorders Patients Undergoing Electroconvulsive Therapy(2015) BILT, Martinus T. van de; PRADO, Carolina M. do; NICOLA, Bruna V.; RIGONATTI, Luiz Felipe; TALIB, Leda L.; RIGONATTI, Sergio Paulo; GATTAZ, Wagner F.- CYP2C9 Intermediate and Poor Metabolizers are More Prevalent in a Sample of Refractory Mood Disorders Patients Undergoing ECT(2014) BILT, Martinus T. van de; PRADO, Carolina M. do; RIGONATTI, Luiz F.; RIGONATTI, Sergio P.; TALIB, Leda L.; GATTAZ, Wagner F.
- Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment(2015) BILT, M. T. van de; PRADO, C. M.; OJOPI, E. P. B.; SOUSA, R. T.; LOCH, A. A.; ZANETTI, M. V.; TALIB, L. L.; GATTAZ, W. F.
conferenceObject Refractoriness in Schizophrenia is not Associated with Cyp2d6 and Cyp2c19 Genotypes(2012) BILT, Martinus T. van de; PRADO, Carolina M.; OJOPI, Elida P. B.; ZANETTI, Marcus V.; LOCH, Alexandre A.; SOUSA, Rafael A. T.; MACHADO-VIEIRA, Rodrigo; GATTAZ, Wagner F.Background: All genes that encode the CYP450 enzymes are highly polymorphic, leading to different metabolic profiles. While for antidepressants it’s possible to make dose adjustments based on the CYP2D6 and CYP2C19 genotypes, there are currently no evidences validating genotype based adjustments for antipsychotics. Therefore, we aimed to investigate the hypothesis that the prevalence of ultra-rapid metabolizers of neuroleptics would be increased among refractory schizophrenia patients. Methods: 89 schizophrenia patients were enrolled and divided in two groups: 59 refractory patients according to IPAP algorithm (International Psychopharmacology Algorithm Project) and 30 non-refractory patients. Polymorphisms in CYP2D6 and CYP2C19 genes were evaluated by allelic discrimination using the TaqMan® system. The following alleles were investigated: CYP2D6*1, *2, *3, *4, *5, *6, *9, *10, *15, *17, *29, *35, *39, *40, *41 beyond copy number variations and alleles CYP2C19*1, *2, *3 and *17. The phenotypes were classified in extensive metabolizers (EMs), poor metabolizers (PMs), intermediary metabolizers (IMs) and ultra-rapid metabolizers (UMs). Results: The distribution of the CYP2D6 and CYP2C19 phenotypes were as follows: CYP2D6: - Non-refractory: 13.3%PM + IM, 86.6%EM and 0.0% UM - Refractory: 13.5%PM + IM, 86.4%EM and 0.0%UM CYP2C19: - Non-refractory: 16.6%PM + IM, 53.3%EM and 30.0% UM - Refractory: 27.1%PM + IM, 40.6%EM and 32.2%UM Statistical analysis showed no significant difference between the distribution of the CYP2D6 phenotypes (p=0.244) and CYP2C19 predicted phenotypes (p = 0.755) among the two groups. Conclusions: Our findings do not reinforce the inclusion of genotyping of these genes as a tool in the clinical decision making in refractory schizophrenia.- ABCB1 Polymorphism may be Related to Refractoriness in a Sample of Mood Disorders Patients Undergoing ECT(2014) PRADO, Carolina M. do; BILT, Martinus T. van de; RIGONATTI, Luiz F.; RIGONATTI, Sergio P.; TALIB, Leda L.; GATTAZ, Wagner F.